Le Lézard
Classified in: Health
Subjects: NPT, SVY

New Gut Microbiome Research Points to Positive Impact on Memory and Mood from Peanut Consumption

ALBANY, Ga., Sept. 26, 2023 /PRNewswire/ -- Research from the University of Barcelona on the gut microbiota has found that daily consumption of peanuts and peanut butter can produce compounds in the gut that help improve memory and reduce stress response, including anxiety and depression, in healthy young adults. Findings from the ARISTOTLE study were published online in the Journal of Functional Foods this September and shared by The Peanut Institute

The study was conducted to explore what's known as the gut-brain axis, which is a relatively new area of research that examines the biochemical communication between the gut and brain. The researchers used a novel method to identify phenolic compounds derived from digesting peanuts and peanut butter and how those compounds can promote better brain health.

When compared to the control group, researchers found that those who consumed peanuts and peanut butter had higher levels of microbial phenolic metabolites (MPMs), which are compounds that can cross the blood-brain barrier and reach brain cells to protect them. Earlier results from the ARISTOTLE trial showed that participants who consumed peanuts and peanut butter experienced an improvement in memory and stress response, largely due to polyphenols in peanuts. 

The new findings confirm the ability of the gut microbiota to potentially produce compounds from peanut polyphenols that can improve brain response. The study showed that MPMs were associated with an improvement in memory and reduced stress. 

"Peanuts and peanut butter may have a beneficial effect on the gut microbiota because they are rich in prebiotic fiber and polyphenols," says Dr. Isabella Parilli Moser, first author of the study. "Due to their very poor absorption, fiber and most polyphenols directly reach the colon, where they are metabolized by the gut microbiota, giving rise to new compounds (MPMs), which can have beneficial effects on the brain."

Dr. Sara Hurtado-Barroso, co-author of the study, adds, "Prebiotic substances present in peanuts and peanut butter, such as polyphenols, may positively affect cognition and mood by promoting production of microbial phenolic metabolites." 

The six-month, randomized controlled trial was conducted with 63 healthy participants (44 females and 19 males) who were 18 to 33 years of age. The participants, who were mostly students, were from the University of Barcelona in Spain and consumed either one handful (25 grams) a day of roasted peanuts with skins or two tablespoons (32 grams) a day of peanut butter or two tablespoons (32 grams) a day of a control butter.

The young men and women followed their regular diet and consumed the peanut products at any time of the day. Wine, grapes, dark chocolate with more than 70% cacao and berries were excluded from the participants' diets due to their high levels of resveratrol, an antioxidant present in peanuts. In addition, other nuts were excluded from the diet due to similar nutritional composition. 

"More and more research is looking at our gut microbiome and how it plays an integral role in affecting our immune system, brain health and other body functions," says Dr. Samara Sterling, a nutrition scientist and research director for The Peanut Institute. "These findings are exciting because the students consumed a relatively small amount of peanuts each day but the impact on their memory and mood was statistically significant."

The research is part of Dr. Isabella Parilli-Moser's PhD thesis, mentored by Dr. Rosa M. Lamuela-Raventós at the University of Barcelona (Department of Nutrition, Food Sciences and Gastronomy, XIA, School of Pharmacy and Food Sciences, at the INSA-University of Barcelona and CIBEROBN). 

It was supported by funding from The Peanut Institute, PID2020-114022RB-I00 and CIBEROBN from the Instituto de Salud Carlos III, ISCIII from the Ministerio de Ciencia, Innovación y Universidades, (AEI/FEDER, UE), Generalitat de Catalunya (GC) [2021-SGR-00334]. INSA-UB is Maria de Maeztu Unit of Excellence (grant CEX2021-001234-M funded by MICIN/AEI/FEDER, UE). None of the funders had a role in the study design, implementation, analysis or interpretation of the data or the writing of the manuscript.

Based in Albany, Ga., The Peanut Institute is a non-profit organization supporting nutrition research and developing educational programs to encourage healthful lifestyles that include peanuts and peanut products. The Peanut Institute pursues its mission through research programs, educational initiatives and the promotion of healthful lifestyles to consumers of all ages. As an independent forum, The Peanut Institute is uniquely positioned to work with all segments of the food industry, the research community, academia, consumer organizations and governmental institutions.


Isabella Parilli-Moser, Ricardo López-Solís, Inés Domínguez-López, Anna Vallverdú-Queralt, Sara Hurtado-Barroso, Rosa M Lamuela-Raventós, Consumption of peanut products enhances the production of microbial phenolic metabolites related with memory and stress response: Results from the ARISTOTLE trial, Journal of Functional Foods, Volume 108, 2023, 105746, ISSN 1756-4646, https://doi.org/10.1016/j.jff.2023.105746.

SOURCE The Peanut Institute

These press releases may also interest you

at 12:35
Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882. The data was also presented today by...

at 12:30
Blueprint Medicines Corporation today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH)...

at 12:05
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented details from the Rallybio Fetal and...

at 12:05
Genmab A/S and AbbVie today announced new data from the ongoing phase 1/2 EPCOREtm NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall...

at 12:00
AbbVie and Genmab A/S announced today that adult patients with relapsed/refractory (R/R) follicular...

at 11:35
bluebird bio, Inc. ("bluebird bio" or "bluebird") today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel...

News published on and distributed by: